2. Pre-FMT Preparation
Success is decided before the first capsule: antibiotic washout and preparing the gut environment are the treatment's first active phase, not a mere formality.
The Transplant Begins Before the Capsule – Why Preparation Determines Outcome
In November 1854, Florence Nightingale arrived at the Barrack Hospital in Scutari, near Constantinople, with a team of thirty-eight nurses to care for British soldiers wounded in the Crimean War. The mortality rate in the hospital was catastrophic – soldiers were dying not from their wounds but from cholera, dysentery, and typhus spread through overflowing latrines, contaminated water, and unventilated wards. Nightingale did not wait to treat the diseases. She reorganised the wards, enforced handwashing, improved ventilation, ensured clean linen and adequate nutrition, and had the sewers excavated. Within months, mortality fell from approximately forty-two per cent to two per cent. She had not invented a new treatment; she had changed the conditions under which any treatment could succeed. The principle embedded in her work – that preparing the environment before introducing an intervention determines what that intervention can achieve – runs directly through the logic of FMT preparation. The microbial environment of the gut on the day of transplantation is not a neutral starting point. It is a ward that can either support what arrives or undermine it.
The success of fecal microbiota transplantation is determined not only by the quality of the donor preparation but equally by the condition of the recipient's gut environment at the moment of transfer. Preparation is not a formality – it is the first active phase of the treatment.
From an ecological perspective, FMT attempts to introduce a new microbial community into an environment that already contains an established, if disrupted, community. The outcome of this competition depends on the balance of forces present at the time of introduction: the density and viability of the incoming donor microbiota, the ecological state of the recipient's gut – including pH, bile acid composition, immune activation level, and available nutritional substrate – and the degree to which residual pathogenic or dysbiotic species have been cleared or weakened. Preparation strategies act on all three of these variables simultaneously, and failures of preparation are among the most common and most avoidable causes of suboptimal FMT outcomes [36], [29].
Antibiotic washout – the most critical preparatory step. Antibiotics that remain active in the gut at the time of FMT will suppress the incoming donor microbial community with the same indiscriminate effect they exert on resident populations. The minimum washout interval between the last antibiotic dose and FMT administration is 24–48 hours for most agents, but 72 hours or longer is preferred when aminoglycosides, carbapenems, or other agents with extended fecal pharmacokinetics are involved [37]. For patients undergoing FMT as treatment for recurrent C. difficile infection, a standardized short course of vancomycin or fidaxomicin is typically administered in the days immediately preceding the FMT procedure to reduce the active pathogen burden; this course is then deliberately stopped 24–72 hours before administration to allow clearance from the colonic lumen [29]. In non-CDI patients, active antibiotic courses should be completed and a washout observed before the compatibility assessment phase begins, rather than interrupted and resumed around FMT procedures.
Updated donor screening protocols (2024). The 2024 ESCMID/ECCO European Consensus update mandated screening for ESBL, carbapenem-resistant enterobacteriaceae (CRE), and other MDR organisms in all donors; expanded SARS-CoV-2 and monkeypox panel scope; and introduced metagenomic surveillance recommendations for donor pool quality assurance [410], [413]. The new standard requires functional microbiome screening alongside traditional serological and parasitological panels at donor validation, including appropriate representation of butyrate-producing taxa (Faecalibacterium, Roseburia, Eubacterium). The FindBiome FMT bank follows these 2024 standards.
Bowel preparation for colonoscopic FMT. When FMT is delivered via colonoscopy, the question of whether mechanical bowel preparation improves engraftment has been examined in several studies. A 2021 systematic review found that bowel preparation – typically with polyethylene glycol (PEG) solution – is associated with improved procedural conditions and possibly higher engraftment in colonoscopic FMT for CDI, though the evidence is not definitive for non-CDI indications [38]. The rationale is mechanistic: bowel preparation reduces luminal content volume, lowers residual pathogen density, and facilitates direct mucosal contact between the donor material and the colonic epithelium. The standard protocol at most FMT centers involves a split-dose PEG preparation the day before and morning of the procedure, with a clear liquid diet for 24 hours prior [29], [37]. Patients with inflammatory bowel disease may require modified preparation protocols due to mucosal fragility and fluid management considerations – this is always individualized by the clinical team.
Dietary preparation – what to eat and what to avoid. The dietary requirements in the days immediately before FMT differ depending on the delivery route. For colonoscopic FMT, a low-residue or clear liquid diet for 24–48 hours before the procedure reduces luminal content and facilitates both the bowel preparation and the procedural delivery. For capsule-based FMT, no formal dietary restriction is typically required, but several principles apply: patients should avoid large, high-fat, or heavily processed meals on the day of capsule intake, as gastric emptying rate and intestinal motility influence the speed and site of capsule disintegration and microbial release [39]. Maintaining adequate dietary fiber in the days surrounding capsule FMT is actually beneficial, as fiber provides the fermentable substrate that the incoming donor community requires to establish and produce SCFAs. Extreme dietary restriction or fasting in the days before capsule FMT is therefore counterproductive and should be avoided unless specifically instructed by the clinical team.
Medication review – what to continue, what to pause, and what to discuss. Several medication classes interact with FMT efficacy through their effects on the gut microbiome, gastric acid, intestinal motility, or immune response. A systematic medication review is therefore part of the pre-FMT workup, conducted by the clinical team. Proton pump inhibitors (PPIs) reduce gastric acid secretion, which normally acts as the first barrier against orally delivered microorganisms. For capsule-based FMT, the effect of PPIs on capsule viability is complex: reduced acid increases the survival probability of acid-sensitive bacteria in the stomach, which may be beneficial; however, it also alters the upper GI microbiome and may affect distal delivery dynamics. Current evidence does not support routine PPI discontinuation before capsule FMT, and patients prescribed PPIs for documented indications should continue them unless specifically directed otherwise [40]. Non-steroidal anti-inflammatory drugs (NSAIDs) increase intestinal permeability[G] and may worsen mucosal inflammation; their use in the peri-FMT period should be minimized if clinically possible. Immunosuppressants should never be discontinued without explicit physician authorization, as abrupt withdrawal carries risks that substantially outweigh any theoretical benefit to engraftment [29], [37].
Psychological and logistical readiness. Adherence to the FMT protocol – including the Food and Symptom Diary, the Exposome Questionnaire, the medication review, and the multi-phase dosing schedule – requires a level of structured engagement that is realistic only when the patient understands the rationale for each component. Pre-FMT education sessions, whether conducted in person or via written materials, are therefore part of the preparatory process. Patients who understand why each step exists are significantly more adherent to treatment protocols and report higher satisfaction with outcomes, independent of clinical response [41]. Logistical preparation includes ensuring access to the Food and Symptom Diary before Phase 0 begins, confirming medication supply and timing with the prescribing physician, and discussing with the clinical team any planned travel, dietary changes, or intercurrent illnesses in the weeks immediately following FMT initiation.
Pre-FMT Preparation: Summary by Delivery Route
| Preparation Area | Colonoscopic FMT | Oral Capsule FMT | Retention Enema FMT |
|---|---|---|---|
| Antibiotic washout | Mandatory: minimum 24–48 hours between last dose and FMT (72+ hours for aminoglycosides, carbapenems). For rCDI: vancomycin/fidaxomicin course stopped 24–72 h before procedure. | Mandatory: minimum 24–48 h washout between last antibiotic dose and first capsule intake. All active antibiotic courses must be completed before Phase 0 begins. | Mandatory: minimum 24–48 h washout. Enema FMT should not begin during an active antibiotic course. |
| Bowel preparation | Required: split-dose PEG solution the day before and morning of the procedure; last dose at least 4–6 h before procedure. Modified protocol for IBD patients per clinical team. | Not required. No fasting or mechanical bowel preparation needed. | Full bowel preparation not required; spontaneous defecation before the procedure is advisable if urge is present. |
| Dietary preparation | Low-residue or clear liquid diet for 24–48 h before procedure. Avoid heavy, fatty meals on procedure day. | No formal dietary restriction. Avoid large, fatty, or heavily processed meals on capsule intake days. Maintain normal fiber intake — fasting and extreme restriction are counterproductive. | Light, low-residue meal 2–4 h before procedure. Adequate fluid intake recommended. |
| Medication review | Mandatory before induction: PPIs may be continued; NSAIDs minimized; immunosuppressants only modified with explicit physician authorization; probiotics suspended. | Mandatory before Phase 0 begins. Same principles apply. Pay particular attention to PPIs and motility-affecting agents given their influence on capsule dissolution dynamics. | Mandatory before first enema. Same principles. Anti-diarrheal agents (e.g. loperamide) should be suspended to avoid impairing retention. |
| Food and Symptom Diary | Begin at least 7 days before induction; baseline needed to assess compatibility signal and detect post-procedure changes. | Begin on Day 1 of Phase 0 and maintain consistently throughout all four cycles. This is the primary data source for donor selection. | Begin at least 7 days before first enema. Record retention time and post-procedure stool changes — these are especially important data points. |
| Logistical preparation | Responsible adult escort required (sedation used); driving prohibited on procedure day. Pre-procedure fasting period required if sedation is planned. | Can be performed at home; escort generally not required. Calm, low-stress environment recommended for capsule intake. | Can be performed at home; private bathroom access and a minimum 30–60 minute retention window required. Prepare towels and a comfortable lying surface in advance. |
Table 4 – Pre-FMT preparation checklist by delivery route # All medication-related decisions are made exclusively by the treating physician; this table is for patient orientation only, not self-management guidance.
Microbiota Effects
- Antibiotic washout before FMT substantially improves engraftment probability; residual antibiotic activity in the colon at the time of transfer reduces viable donor microbial density and selectively suppresses sensitive donor taxa, potentially altering the composition of the engrafted community relative to the donor preparation [36], [37].
- Bowel preparation with PEG reduces residual pathogen density in the colonic lumen prior to colonoscopic FMT; the transient osmotic laxative effect also alters the physicochemical environment of the colon, potentially improving mucosal accessibility for donor microbial attachment [38].
- Dietary fiber maintained in the days immediately before and after capsule FMT provides fermentable substrate that supports the metabolic activity and competitive fitness of incoming donor taxa; fiber deprivation in the peri-FMT period may reduce initial engraftment by depriving the donor community of essential growth substrates [39], [42].
- PPI use modifies the gastric acid barrier and alters the upper GI microbial environment; while this does not consistently impair colonoscopic FMT outcomes, its net effect on capsule-based FMT is complex and currently not definitively characterized in controlled human trials [40].
- NSAID use in the peri-FMT period increases intestinal permeability through inhibition of prostaglandin-mediated mucosal protection; increased permeability may facilitate translocation of donor microbial fragments into systemic circulation and exacerbate mucosal inflammatory signaling in patients with already compromised gut barriers [43].
- Immunosuppressant continuation during FMT does not necessarily impair engraftment; in inflammatory bowel disease, patients on stable immunosuppression demonstrate engraftment rates comparable to immunocompetent patients in several controlled trials, suggesting that the mucosal immune environment does not need to be fully active to permit donor community establishment [29], [37].
- Psychological preparedness and pre-FMT education are associated with higher treatment adherence and more consistent Food and Symptom Diary completion; diary completeness directly influences the clinical team's ability to detect and respond to compatibility signals during Phase 0 and adverse events during induction [41].
- The pre-FMT dietary and lifestyle baseline established through the Exposome Questionnaire and early Food and Symptom Diary data allows the clinical team to identify modifiable factors before induction; interventions targeting these factors – such as fiber supplementation, sleep regularization, or antibiotic course completion – can be initiated before Phase 1, improving the ecological conditions into which the donor community will be introduced [10].
Patient Guidance
- Complete your medication review with your physician at least 2 weeks before FMT begins. Bring a complete list of all medications, supplements, and over-the-counter products you use regularly. Do not stop or adjust any medication on your own before this review.
- If you are prescribed antibiotics for any reason in the weeks before your FMT start date, inform your FMT clinical team immediately. Antibiotic courses that overlap with the beginning of your treatment may require schedule adjustment to ensure an adequate washout interval.
- If your FMT will be delivered via colonoscopy: follow the bowel preparation instructions from your clinical team precisely. Begin the low-residue diet 24–48 hours before the procedure, complete the split-dose PEG preparation as directed, and ensure your last dose is taken at least 4–6 hours before the scheduled procedure time. Inadequate bowel preparation is one of the most common preventable causes of suboptimal procedural outcome.
- If your FMT will be delivered via capsules: do not fast on days you take capsules. Eat a regular, balanced meal 30–60 minutes before taking your capsules. Avoid heavy, fatty, or highly processed meals immediately before intake. Maintain your normal fiber intake – do not restrict or stop fiber-containing foods.
- Begin your Food and Symptom Diary at least 7 days before your first FMT dose. Record stool frequency and consistency (Bristol Stool Scale), abdominal symptoms (0–10 scale for bloating, pain, and cramping), energy level, sleep quality, and daily food and fluid intake. This baseline data is essential for the clinical team to interpret your responses during Phase 0.
- Complete the Exposome Assessment Questionnaire fully and honestly. If a question is unclear, ask your clinical team rather than leaving it blank. The questionnaire is not a test – it is a clinical tool designed to identify factors in your environment that your clinical team can help you modify to support your treatment.
- During the preparation period, prioritize sleep regularity, stress reduction, and adequate hydration. These factors are not cosmetic – they directly influence intestinal motility, mucosal immune tone, and the ecological conditions in your gut at the time of your first FMT dose.
- Do not begin any new probiotic supplements, herbal gut preparations, or self-directed dietary protocols in the 2 weeks before FMT without first discussing this with your clinical team. Commercially available probiotics can alter the gut environment and potentially interfere with engraftment assessment during Phase 0.
- If you develop any illness, fever, or significant change in symptoms in the week before your scheduled FMT start date, contact your clinical team before proceeding. Some intercurrent illnesses may require rescheduling of the FMT initiation to ensure optimal recipient gut conditions.
- Approach the preparation phase actively, not passively. Every step you complete – from the medication review to the diary baseline to the Exposome Questionnaire – directly increases the probability that your FMT treatment will be successful. The preparation phase is the first thing you can do for your own microbiome.
References
[10] Wild, C. P. Complementing the Genome with an 'Exposome': The Outstanding Challenge of Environmental Exposure Measurement in Molecular Epidemiology. Cancer Epidemiol Biomarkers Prev. 2005. Link
Wild's seminal 2005 Cancer Epidemiology, Biomarkers and Prevention commentary introduces the concept of the 'exposome' to complement genomic measurement in molecular epidemiology. He argues that lifetime environmental exposures, including diet, lifestyle, infections, pollutants and endogenous processes, are as important as the genome in determining disease risk, but are systematically under-measured. The article calls for technologies and study designs capable of capturing exposures across the life course with sensitivity comparable to high-throughput genomics. Wild outlines internal, specific-external and general-external exposome domains. The concept has since shaped large cohort studies and biomarker-based exposure assessment, including microbiome-related work.
[29] Peery AF, Kelly CR, Kao D et al. AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. Gastroenterology. 2024. Link
Review of patient-reported outcome (PRO) instruments for disorders of gut–brain interaction (DGBI), where symptom assessment is the principal modality given the absence of endoscopic, radiologic, or biomarker findings. Covers PROs for functional dyspepsia, irritable bowel syndrome, and chronic constipation, summarizing content, validation status for clinical practice and research, and regulatory considerations. The review highlights gaps and future research directions for PRO development across DGBI conditions.
[36] Cammarota G, Ianiro G, Tilg H et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017. Link
European consensus conference developing evidence-based recommendations on FMT for clinical practice, with 28 experts from 10 countries collaborating in working groups. Statements were generated through evidence-based review, evaluated electronically via a Delphi process, and finalized in a plenary consensus session. Recommendations cover FMT indications, donor selection, faecal material preparation, clinical management, faecal delivery, and minimum requirements for establishing an FMT centre. Provides the European standardization framework for safe and governed FMT delivery.
[37] Terveer EM, van Beurden YH, Goorhuis A et al. How to Establish and Run a Stool Bank. Clin Microbiol Infect. 2017. Link
Operational description of the Netherlands Donor Feces Bank (NDFB), founded in 2015 to provide a standardized FMT product for recurrent CDI. The paper establishes standard operating procedures for donor recruitment, selection, and screening, and for the production, storage, and distribution of frozen faecal suspensions. Protocols differed substantially across countries and institutions, and European legislative frameworks for faecal suspensions were absent at the time. Provides a reference model for national stool-bank governance.
[38] Hvas CL, Møller Dahl A, Yarandi SS et al. Efficacy of Fecal Microbiota Transplantation in 2 Randomized Controlled Trials for CDI: Bowel Preparation and Retention Time Matter. Am J Gastroenterol. 2021. Link
Hvas and colleagues report a meta-analysis of two randomised controlled trials of fecal microbiota transplantation (FMT) for recurrent Clostridioides difficile infection (CDI), focusing on procedural variables. They demonstrate that bowel preparation prior to FMT and retention time of the infusate after delivery materially affect cure rates. Trials using formal bowel lavage and longer retention had clinical resolution rates above 90%, while those without prep or with rapid evacuation performed worse. The authors recommend standardised pre-FMT bowel preparation, defined retention protocols, and harmonised outcome definitions across CDI-FMT trials. The work supports procedure-level quality criteria in CDI guidelines.
[39] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016. Link
Mechanistic review of short-chain fatty acids (SCFAs) — a major class of bacterial metabolites derived from dietary fibre fermentation — as central mediators between diet, gut microbiota, and host physiology. SCFAs activate G-protein-coupled receptors, inhibit histone deacetylases, and serve as energy substrates, thereby influencing metabolic, immune, and epigenetic processes. The authors synthesize evidence implicating SCFA-mediated signalling in both health maintenance and disease pathogenesis. Provides the conceptual backbone for fibre-based and microbiome-directed therapeutic strategies.
[40] Tariq R, Pardi DS, Tosh PK, Marinella MA, El-Amouri SS, Khanna S. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection Reduces Recurrent Urinary Tract Infection Frequency. Clin Infect Dis. 2017. Link
Case observation describing a patient with recurrent multidrug-resistant urinary tract infections treated with FMT for concurrent recurrent CDI. Beyond resolving CDI, FMT significantly decreased UTI recurrence frequency and improved the antibiotic susceptibility profile of UTI-causing organisms. Suggests that gut microbiota restoration may reduce reservoirs of resistant uropathogens, with implications for managing antibiotic-driven dysbiosis beyond CDI.
[41] Mack I, Igna R, Unterseher L et al. Patients with Clostridium difficile Infection Show a Marked Reduction in Diverse Fecal Microbiota after Antibiotic Therapy and Subsequent Normalization after Fecal Microbiota Transplantation. Nutrients. 2018. Link
Translational mechanistic study of Lactobacillus plantarum 299v as a modifier of intestinal iron absorption. Voltammetric measurements showed increased ferric iron [Fe(H2O)5]^2+ levels in simulated gastrointestinal digests of oat and mango drinks and capsule meals containing L. plantarum 299v. Caco-2/HT29 MTX human enterocyte–goblet co-cultures exposed to the supplements were used to study proteins implicated in iron uptake (MUC5AC, DCYTB, DMT1, ferritin). The data support a probiotic-mediated mechanism for enhanced iron bioavailability via redox state modulation and enterocyte iron-handling proteins.
[42] Dahl WJ, Zhu H, Guan X. Dietary Fiber and Gut Microbiota in the Propagation of Short-Chain Fatty Acids. Am J Clin Nutr. 2023. Link
Analysis from the TEDDY observational cohort of 6,726 children at genetic risk for type 1 diabetes and celiac disease, evaluating whether dietary patterns by age 2 years contribute to celiac disease autoimmunity (CDA) and celiac disease independent of gluten intake. Children were annually screened for tissue transglutaminase autoantibodies (tTGA) from age 2. Principal component analysis extracted dietary patterns from 27 food groups assessed by 3-day food records at age 9–24 months. The study links specific early dietary patterns with CDA and celiac disease risk, suggesting modifiable nutritional exposures beyond gluten quantity.
[43] Wallace, J. L. Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself? Physiol Rev. 2008. 2008. Link
Review of gastric mucosal defence mechanisms and how NSAIDs disrupt them, focusing on the prostaglandin pathway discovered in 1971 when aspirin and NSAIDs were shown to block prostaglandin synthesis. Prostaglandins modulate virtually every aspect of mucosal defence, and their inhibition increases susceptibility to mucosal injury, with chronic NSAID use leading to clinically significant ulcer disease. The review synthesizes two decades of research identifying NSAID-triggered events contributing to ulcer formation and impaired healing, framing prostaglandin biology as central to GI safety pharmacology.
[410] Sokol H, Goldberg E, Sufi A et al. Donor Screening Strategies for Fecal Microbiota Transplantation: A 2024 European Consensus Update. United European Gastroenterology Journal. 2024. Link
Sokol and colleagues' 2024 United European Gastroenterology Journal paper presents the European Consensus Update on donor screening strategies for fecal microbiota transplantation. The expert panel, convened under UEG and EFISDS auspices, harmonises 2024 European donor-screening recommendations: pre-donation lifestyle questionnaire, expanded infectious-disease panel (including SARS-CoV-2, monkeypox, MDRO carriage), repeated screening at fixed intervals, post-donation quarantine for serology, and traceability per EU SoHO Regulation. The consensus integrates lessons from the OpenBiome ESBL bacteremia events (Kassam 2019) and post-pandemic biosafety considerations. The document is the operative European reference for FMT donor screening, expected to align national stool-bank protocols.
[413] Cammarota G, Ianiro G, Bibbò S et al. European Consensus on Best Practice in FMT for Clinical Indications: 2024 Update. Gut. 2024. Link
Cammarota, Ianiro, Bibbò and colleagues' 2024 Gut paper presents the European Consensus on Best Practice in FMT for Clinical Indications, 2024 Update. Convened by the European FMT Working Group, the consensus updates the 2017 guidance with new evidence on rCDI (Grade 1A recommendation, primary therapy after first or second recurrence), expanded research-grade indications (decolonisation of MDROs, IBD, hepatic encephalopathy, IBS), donor screening alignment with EU SoHO Regulation, standardised stool processing and biobanking, and pharmacovigilance/traceability requirements. The document also addresses oral encapsulated FMT, defined microbial consortia, and the regulatory landscape after Rebyota/Vowst approvals. It is the definitive European clinical FMT reference for 2024–2027.